Aion Therapeutic Inc.
ANTCF
$0.00
-$0.02-90.56%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 546.14% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 546.14% | -- | -- | -- | -- |
| Cost of Revenue | 1,566.44% | -- | -- | -- | -- |
| Gross Profit | 182.77% | -- | -- | -- | -- |
| SG&A Expenses | 88.61% | 138.35% | 121.40% | 46.49% | -1.99% |
| Depreciation & Amortization | 688.39% | 1,556.82% | 490.91% | 137.40% | -21.68% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 179.30% | 234.91% | 189.41% | 71.51% | -16.09% |
| Operating Income | -80.98% | -90.72% | -77.99% | -29.72% | 33.81% |
| Income Before Tax | -499.88% | -614.19% | -612.17% | -2,469.97% | 37.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -499.88% | -614.19% | -612.17% | -2,469.97% | 37.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -499.88% | -614.19% | -612.17% | -2,469.97% | 37.60% |
| EBIT | -80.98% | -90.72% | -77.99% | -29.72% | 33.81% |
| EBITDA | -270.95% | -320.56% | -83.15% | 19.03% | 67.86% |
| EPS Basic | -172.09% | -171.11% | -172.73% | -1,090.91% | 52.75% |
| Normalized Basic EPS | 29.63% | 31.25% | 37.50% | 25.71% | 46.00% |
| EPS Diluted | -172.09% | -171.11% | -160.87% | -907.69% | 53.76% |
| Normalized Diluted EPS | 29.63% | 31.25% | 37.50% | 18.75% | 42.55% |
| Average Basic Shares Outstanding | 129.80% | 162.42% | 131.73% | 81.07% | 38.05% |
| Average Diluted Shares Outstanding | 129.80% | 162.42% | 131.73% | 71.02% | 30.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |